AIDS TREATMENT NEWS Issue #372, October 19, 2001
John S. James
The most complete recent list we have seen of anti-HIV drugs in development -- over 60 total, including the approved drugs -- was posted recently by Ben Cheng of Project Inform, on the Web site of the new AIDS Treatment Activist Coalition.
The list, at http://www.atac-usa.org/RDACommittee.html (scroll down, or click on "Chart on drugs in development", has the generic or chemical name of each compound, the class of drug (nucleoside analog, protease inhibitor, etc.), the phase of development (preclinical, phase I, phase II, phase III, or approved), and the pharmaceutical company doing the work.
For another extensive list of drugs in (or formerly in) development, see the Treatment Action Group (TAG) Web site: http://www.aidsinfonyc.org/tag/science/pipeline.html
For more information about some of the more prominent new drugs currently being researched, see "New Agents for Anti- HIV Therapy," by Joseph J. Eron Jr., M.D., and Robert L. Murphy, M.D. It is available on the Medscape site, http://hiv.medscape.com (click on 'New Agents for Anti-HIV Therapy' if this link is still there, or search the site for the author's last name, and look for the title in the results returned). Note: The Medscape site requires registration, but registration is free, and it need be done only once (provided you remember the user ID and password you choose). Most articles on continuing-education medical sites remain online for one year.
011019
ATN37206
Copyright © 2001 - AIDS Treatment News. Permission granted for noncommercial reproduction, provided that our address and phone number are included if more than short quotations are used. Subscription lists are kept confidential. AIDS Treatment News, Subscription and Editorial Office: 1233 Locust St., 5th floor Philadelphia, PA 19107 800/TREAT-1-2 toll-free email: aidsnews@critpath.org http://www.aidsnews.org
Subscription Information: Call 800/TREAT-1-2: Businesses, Institutions, Professionals: $270/year. Includes early delivery of an extra copy by email. Nonprofit organizations: $135/year. Includes early delivery of an extra copy by email. Individuals: $120/year, or $70 for six months. Special discount for persons with financial difficulties: $54/year, or $30 for six months. If you cannot afford a subscription, please write or call. Outside North, Central, or South America, add air mail postage: $20/year, $10 for six months. Back issues available. Fax subscriptions, bulk rates, and multiple subscriptions are available; contact our office for details. Please send U.S. funds: personal check or bank draft, international postal money order, or travelers checks. VISA, Mastercard, and purchase orders also accepted. ISSN # 1052-4207
AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, iMetrikus, Inc., the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2001. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1990, 2001. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. Feedback/Contact Us.